Tag: pharmaceuticals
-
Challenges Seek Solutions for Chronic Diseases, Oral Drugs in Animals
Two new crowdsourcing competitions announced this week are seeking ideas on broadening the scope of drugs being developed for companion animals, and making drugs easier to give to pets and farm animals.
-
Drug Discovery System Designed to Identify Difficult Targets
A lab in the U.K. developed a system for discovering new therapies that identify therapy targets linked to enzymes, some found in neurodegenerative diseases, previously considered too difficult to address.
-
Experimental Drug Extends Survival, Reverses Inherited ALS Damage
An experimental drug designed to silence a protein associated with inherited forms of amyotrophic lateral sclerosis, or ALS, is shown in tests with lab rodents to extend survival and reverse some neuromuscular damage.
-
Univ. Spin-Off Developing Myelin Disease Treatments Unveiled
A spin-off enterprise from Case Western Reserve University is developing therapies designed to restore the myelin sheath around nerve cells destroyed in multiple sclerosis and other neurological disorders.
-
GSK, 23andMe Ink Precision Meds Discovery Deal
Consumer genetics company 23andMe signed a 4-year agreement to help drug maker GlaxoSmithKline find more precise drug targets and recruit clinical trial participants likely to respond to treatments.
-
Merck, Biopharma Partner on Cell-Free Immune System Therapies
Drug maker Merck is acquiring the rights to therapies for cancer and autoimmune disorders based on a technology for developing synthetic proteins from a process that bypasses live cells.
-
Computer-Aided Bone Graft Process Devised with Stem Cells
A tissue engineering team developed a process that includes computer-assisted design for personalized grafts derived from a patient’s own stem cells, to repair bone defects caused by trauma or disease.
-
More Damage Detected from Crispr-Cas9 Edits
A genetics lab in the U.K. revealed that a leading technique for editing genomes produces more unwanted damage to the edited genomes than previously understood.
-
A.I. Drug Discovery Company Gains $32M in Early Funds
A company using genomic databases and artificial intelligence to discover new therapies for neurodegenerative diseases is raising $32 million in its first venture funding round.
-
Exosome Technology Acquired for TBI, Stroke Therapies
A company developing therapies for brain injuries and neurodegenerative disorders is acquiring the rights to a process that treats these conditions with pieces of RNA transferred in tiny containers call exosomes.